Sign in
4

Changes in Ownership

Oncotelic Therapeutics, Inc. Filed Acc 0001209191-17-003700

Options or other derivatives

  • Chief Scientific Officer acquired 262,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
CHAPLIN DAVID Chief Scientific Officer 2017-01-12 Grant or award · Employee Stock Option (Right to Buy) +262,500 $0.38 $98,438 262,500 D
Loading xslF345X03/doc4.xml…